US government approves Johnson & Johnson’s single-shot COVID-19 vaccine

The J&J vaccine is also under review by the European Union, where deliveries are expected starting in April.
In J&J's 44,000-person global trial, the vaccine was found to be 66% effective at preventing moderate-to-severe COVID-19.
J&J's vaccine is expected to be used widely around the globe because it can be shipped and stored at normal refrigerator temperatures.